Preoperative oral rofecoxib reduces postoperative pain and tramadol consumption in patients after abdominal hysterectomy

Basit Öğe Kaydı
dc.contributor.authorKaramanlioglu, B
dc.contributor.authorTuran, A
dc.contributor.authorMemis, D
dc.contributor.authorTüre, M
dc.date.accessioned2024-06-12T11:18:42Z
dc.date.available2024-06-12T11:18:42Z
dc.date.issued2004
dc.departmentTrakya Üniversitesien_US
dc.description.abstractWe designed this study to determine whether the administration of a preoperative dose of rofecoxib to patients undergoing abdominal hysterectomy would decrease patient-controlled analgesia (PCA) tramadol use or enhance analgesia. Sixty patients were randomized to receive either oral placebo or rofecoxib 50 mg 1 h before surgery. All patients received a standard anesthetic protocol. Intraoperative blood loss was determined. At the end of surgery, all patients received tramadol IV via a PCA-device. Pain scores, sedation scores, mean arterial blood pressure, heart rate, and peripheral oxygen saturation were assessed at 1, 2, 4, 6, 8, 12, and 24 h after surgery. Total and incremental tramadol consumption at the same times was recorded from the PCA-device. Antiemetic requirements and adverse effects were noted during the first postoperative 24 h. Duration of hospital stay was also recorded. The pain scores were significantly lower in the rofecoxib group compared with the placebo group at 6 times during the first 12 postoperative h (P < 0.05). The total consumption of tramadol (627 +/- 69 mg versus 535 +/- 45 mg; P < 0.05) and the incremental doses at 1, 2, 4, 6, 8, and 12 h after surgery were significantly more in the placebo group than in the rofecoxib group. There were no differences between groups in intraoperative blood loss, sedation scores, hemodynamic variables, peripheral oxygen saturation, antiemetic requirements, or adverse effects after surgery. The length of hospital stay was also similar in the groups. We conclude that the preoperative administration of oral rofecoxib provided a significant analgesic benefit and decreased the opioid requirements in patients undergoing abdominal hysterectomy.en_US
dc.identifier.doi10.1213/01.ANE.0000103295.31539.A7
dc.identifier.endpage1043en_US
dc.identifier.issn0003-2999
dc.identifier.issue4en_US
dc.identifier.pmid15041595en_US
dc.identifier.scopus2-s2.0-1642543377en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage1039en_US
dc.identifier.urihttps://doi.org/10.1213/01.ANE.0000103295.31539.A7
dc.identifier.urihttps://hdl.handle.net/20.500.14551/24926
dc.identifier.volume98en_US
dc.identifier.wosWOS:000220491700030en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.ispartofAnesthesia And Analgesiaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectDental Painen_US
dc.subjectMorphine Consumptionen_US
dc.subjectControlled Analgesiaen_US
dc.subjectCelecoxiben_US
dc.subjectInhibitoren_US
dc.subjectDiclofenacen_US
dc.subjectEfficacyen_US
dc.subjectCox-2en_US
dc.titlePreoperative oral rofecoxib reduces postoperative pain and tramadol consumption in patients after abdominal hysterectomyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu